SCHEMBL21153067

SCHEMBL21153067

N=C(N)c1ccc(/N=N/c2c(N)ncc3ccc(Cl)cc23)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.56
KIT P10721 1/20 0.56
NTRK3 Q16288 1/20 0.56
ST14 Q9Y5Y6 1/20 0.38
LMNA P02545 1/20 0.34
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
PLAU P00749 2/20 0.33
F10 P00742 2/20 0.33
F2 P00734 1/20 0.32
PLG P00747 1/20 0.32
PLAT P00750 1/20 0.32
KLK1 P06870 1/20 0.32
PRSS1 P07477 1/20 0.32
MAP4K4 O95819 1/20 0.32
NPFFR1 Q9GZQ6 1/20 0.30
NPFFR2 Q9Y5X5 1/20 0.30
UBE2T Q9NPD8 2/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21153073 0.86 FLT3 (0.56) FLT3KITNTRK3ST14PLAU
SCHEMBL17469650 0.86 FLT3 (0.75) FLT3KITNTRK3ST14LMNA
SCHEMBL17469789 0.83 KIT (0.52) FLT3KITNTRK3ST14LMNA
SCHEMBL21152352 0.79 KIT (0.49) FLT3KITNTRK3ST14
SCHEMBL21153070 0.77 FLT3 (0.56) FLT3KITNTRK3ST14MAP4K4
SCHEMBL17469652 0.72 KIT (0.75) FLT3KITNTRK3ST14PLAU
SCHEMBL17469648 0.72 KIT (0.75) FLT3KITNTRK3ST14PLAU
SCHEMBL17469649 0.72 KIT (1.00) FLT3KITNTRK3ST14PLAU
SCHEMBL21152053 0.71 KIT (0.44) FLT3KITNTRK3LMNAPLAU
SCHEMBL21103118 0.70 FLT3 (0.76) FLT3KITNTRK3LMNAPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, BALTIMORE 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190209548-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B FLT3 2354/4885KIT 2616/4885NTRK3 4453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.